Pipeline and regulatory updates were the focus this week with the FDA approving the first two-drug HIV treatment in the United States and the European Commission (“EC”) granting approval to Johnson & Johnson’s JNJ Tremfya and expanding the label of Novartis’s NVS Tasigna.
Recap of the Week’s Most Important Stories
J&J, Glaxo HIV Drug Gets FDA Nod: J&J and GlaxoSmithKline GSK gained FDA approval for the first two-drug HIV treatment in the United States. Juluca combines two approved HIV drugs - Tivicay (50 mg) and Edurant (25 mg) – into a single, once-daily pill for the maintenance treatment of virologically suppressed HIV-1 infection. The companies expect to make the drug available in U.S. pharmacies from December 11.
Juluca marks the beginning of a new era in HIV treatment with other companies like Gilead also working on bringing better treatments to the market (Read more: J&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen).
EU Nod for J&J Psoriasis Drug: Janssen-Cilag International NV, a J&J company, gained EU approval for its psoriasis drug, Tremfya, for use in adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Approval was expected considering the Committee for Medicinal Products for Human Use (“CHMP”) had adopted a positive opinion in September. The drug was approved in the United States earlier this year in July.
Although the psoriasis market is pretty crowded, about 125 million people across the world are estimated to suffer from psoriasis including 14 million Europeans. 20% of these cases are considered moderate to severe. Tremfya is currently in late-stage development for the treatment of psoriatic arthritis.
Johnson & Johnson is a Zacks Rank #2 (Buy) stock - you can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Roche Presents Data on Hemophilia and Cancer Drugs: Roche RHHBY presented positive data on its recently approved hemophilia drug, Hemlibra, from a late-stage study (HAVEN 3) in adults and adolescents (aged 12 years or older) with hemophilia A without inhibitors to factor VIII. The study met its primary endpoint as well as key secondary endpoints with Hemlibra significantly reducing bleeds.
Roche also presented positive data on a combination of its two cancer drugs, Tecentriq and Avastin, in patients with a type of advanced lung cancer. The drugs plus chemotherapy were found to significantly cut down the risk of disease worsening or death in the first-line treatment of these patients. Roche intends to submit this data to the FDA as well as other regulatory agencies. Although the data is not fully mature, Roche said that initial observations show encouraging overall survival (“OS”) data. The next OS analysis is scheduled for the first half of 2018 (Read more: Roche Reports Positive Data From Tecentriq Combination Study).
Label Expansion for Novartis Cancer Drug: The EC has expanded the label of Novartis’s tyrosine kinase inhibitor (“TKI”), Tasigna (nilotinib), so that it can be used for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP) and pediatric patients with Ph+ CML-CP with resistance or intolerance to prior therapy including Gleevec (imatinib). Approval for this indication was expected given a positive CHMP opinion issued in September. With treatment options being limited for children with CML, there is significant unmet need in this patient population (Read more: Novartis Receives EC Nod for Tasigna Label Expansion).
J&J Seeks Label Expansion for Darzalex: J&J’s Janssen-Cilag International NV is looking to expand the label of its immunotherapy Darzalex so that it can be used in combination with Velcade (bortezomib), melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. Approval would expand the patient population significantly. Regulatory applications have been submitted in the United States as well as the EU. FDA approval would make this the fifth indication for Darzalex in the United States and the first in the frontline setting (Read more: J&J Seeks Darzalex's Label Expansion in First-Line Setting).
J&J has gained 19.2% year to date, compared to the 14.8% rally of the industry it belongs to.
Large Cap Pharmaceuticals Industry 5YR % Return
Large Cap Pharmaceuticals Industry 5YR % Return
The NYSE ARCA Pharmaceutical Index was up 0.2% over the last four trading sessions. Among major stocks, AstraZeneca AZN was up 0.9% while Merck MRK declined 1.5%. Over the last six months, Bristol-Myers BMY was up 14.3% while Glaxo declined 16.2% (See the last pharma stock roundup here: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo).
What's Next in the Pharma World?
Watch out for regulatory and pipeline news from pharma stocks.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY) : Free Stock Analysis Report
Astrazeneca PLC (AZN) : Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report
Novartis AG (NVS) : Free Stock Analysis Report
Johnson & Johnson (JNJ) : Free Stock Analysis Report
GlaxoSmithKline PLC (GSK) : Free Stock Analysis Report
Merck & Company, Inc. (MRK) : Free Stock Analysis Report
To read this article on Zacks.com click here.